CliffBio
small molecule

GVOKE HYPOPEN

GLUCAGON

Loss of exclusivityApril 2036latest FDA-listed patent expiry
CompanyXeris Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameGVOKE HYPOPEN
Active ingredientGLUCAGON
Strength1MG/0.2ML (1MG/0.2ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2019
Marketing statusRX

Listed patents

PatentExpiresType
9649364April 2036product
11590205April 2036product

More from Xeris Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

GVOKE HYPOPEN patent cliff — loss of exclusivity April 2036 | CliffBio